Chu Yu-Waye's Form 4 filing
Fate Therapeutics IncFATE · filed Apr 19, 2023
- Accession no.
- 0001209191-23-024820
- Filed
- Apr 19, 2023
- Trade date
- Apr 18, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $16.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chu Yu-WayeCIK 0001854586 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $6.46 to $6.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2-3.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $6.56 to $6.60 per share.
Referenced by the price of 1 transaction in Table I.